Inclusivity in clinical trials
Rheumatology · 15.07.2026 · 64 (4) · 266-269
DOI: 10.5114/reum/225902 ↗Kurz gefasst
Editorial in der Zeitschrift Rheumatology, online erschienen am 15.07.2026. Verfasst von Maria Maślińska. Beteiligte Einrichtung: Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Clinical trials, with their complex legal and ethical regulations, impose stringent requirements concerning appropriate research methodology, which is focused on examining the most representative aspects of the given clinical problem.While such trials are concentrated on proving safety and efficacy of the tested substance or procedure for the majority of patients, it is may miss out on complications that are inherently associated with a specific minority of individuals.Understanding this aspect is crucial for the researchers themselves, as well as other professionals, most prominently ethicists, who are working on establishing legal and regulatory framework for clinical trials.
Autor:innen und Institutionen
- Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
ORCID-Profile: Maria Maślińska
Zitieren
APA
Maślińska, M. (2026). Inclusivity in clinical trials. Rheumatology, 64(4), 266-269. https://doi.org/10.5114/reum/225902
Vancouver
Maślińska M. Inclusivity in clinical trials. Rheumatology. 2026;64(4):266-269. doi:10.5114/reum/225902
BibTeX
@article{Maliska2026,
author = {Maślińska, Maria},
title = {Inclusivity in clinical trials},
journal = {Rheumatology},
year = {2026},
volume = {64},
number = {4},
pages = {266--269},
doi = {10.5114/reum/225902}
}
EUVIMED